Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the study of lung cancer, and Association for Molecular Pathology Conference Paper uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Agents
  • Lung Neoplasms
  • Patient Selection
  • Protein Kinase Inhibitors
  • Receptor Protein-Tyrosine Kinases
  • Receptor, Epidermal Growth Factor

abstract

  • The 37 guideline items address 14 subjects, including 15 recommendations (evidence grade A/B). The major recommendations are to use testing for EGFR mutations and ALK fusions to guide patient selection for therapy with an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) inhibitor, respectively, in all patients with advanced-stage adenocarcinoma, regardless of sex, race, smoking history, or other clinical risk factors, and to prioritize EGFR and ALK testing over other molecular predictive tests. As scientific discoveries and clinical practice outpace the completion of randomized clinical trials, evidence-based guidelines developed by expert practitioners are vital for communicating emerging clinical standards. Already, new treatments targeting genetic alterations in other, less common driver oncogenes are being evaluated in lung cancer, and testing for these may be addressed in future versions of these guidelines.

publication date

  • June 2013

Research

keywords

  • Conference Paper

Identity

Language

  • eng

PubMed Central ID

  • PMC4162344

Digital Object Identifier (DOI)

  • 10.5858/arpa.2012-0720-OA

PubMed ID

  • 23551194

Additional Document Info

start page

  • 828

end page

  • 60

volume

  • 137

number

  • 6